The Splenic Marginal Zone B-Cell Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Splenic Marginal Zone B-Cell Lymphoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Splenic Marginal Zone B-Cell Lymphoma and features dormant and discontinued products.
GlobalData tracks 35 drugs in development for Splenic Marginal Zone B-Cell Lymphoma by 29 companies/universities/institutes. The top development phase for Splenic Marginal Zone B-Cell Lymphoma is phase ii with 22 drugs in that stage. The Splenic Marginal Zone B-Cell Lymphoma pipeline has 28 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Splenic Marginal Zone B-Cell Lymphoma pipeline products market are: General Hospital of the People’s Liberation Army, BeiGene and AbbVie.
The key targets in the Splenic Marginal Zone B-Cell Lymphoma pipeline products market include B Lymphocyte Antigen CD19, B Lymphocyte Antigen CD20, and Tyrosine Protein Kinase BTK.
The key mechanisms of action in the Splenic Marginal Zone B-Cell Lymphoma pipeline product include B Lymphocyte Antigen CD20 Inhibitor with seven drugs in Phase III. The Splenic Marginal Zone B-Cell Lymphoma pipeline products include six routes of administration with the top ROA being Intravenous and four key molecule types in the Splenic Marginal Zone B-Cell Lymphoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Splenic Marginal Zone B-Cell Lymphoma overview
Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and erode its normal architecture. SMZL may be associated with hepatitis C virus infection in some cases. The diagnosis of SMZL requires the presence of splenomegaly and splenic histology. The bone marrow may show nodular infiltration by neoplastic cells with marginal zone differentiation. Peripheral blood may contain villous lymphocytes with plasmacytoid features. SMZL is an indolent disease that may not require immediate treatment unless symptoms or cytopenias are present. Rituximab-based therapies are effective in most patients, and novel agents are being investigated for relapsed or refractory cases.
For a complete picture of Splenic Marginal Zone B-Cell Lymphoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
